Anika Therapeutics (ANIK) Tops Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.38 +4.78%
Revenue Growth %: +5.9%
Financial Fact:
Total operating expenses: 12.1M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +5.9%
Financial Fact:
Total operating expenses: 12.1M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.04, $0.22 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $27.8 million versus the consensus estimate of $27.8 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbnb (ABNB) call put ratio 1 call to 1.3 puts into quarter results
- United Therapeutics Corp. (UTHR) PT Raised to $720 at Raymond James
- Gordon Haskett Upgrades Wayfair (W) to Buy (1)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
